Xerostomia Therapeutics Market Outlook 2031
The global xerostomia therapeutics market size was valued at USD 2 Billion in 2022 and is anticipated to reach USD 2.80 Billion by 2031, expanding at a CAGR of 3.8% during the forecast period, 2023–2031. The growth of the market is attributed to the increasing demand for chemotherapy and radiotherapy in cancer treatment market.
Xerostomia is a dry mouth condition and is commonly caused due to absent of salivary flow producing mucosal dryness. The rise in chemotherapy and radiation therapy is expected to lead to an increased incidences of xerostomia.
Adoption of radiation and chemotherapy to undergo for the cancer treatment is likely to damage the salivary gland and develop effects such as dryness in mouth. Every year, about 640,000 cancer patients receive chemotherapy treatment that are mainly prescribed by medical practitioners, according to the Centers for Disease Control & Prevention (CDC).
It was estimated that over 3.4 million women suffered from breast cancer in the U.S. in January 1, 2016, as per a report published by American Cancer Society. Around 48% of the women with stage IV breast cancer are most likely to receive chemotherapy or radiation.
Products including saliva substitute gels, lozenges, toothpastes, oral-adhering discs, sugar-free chewing gums patches, mouthwashes & oral rinses, and melts are some of the key medications available in the market.
However, the prices of these products range from USD 10 to 90 and yet there are favorable remuneration policies of these products across several countries. For instance, funds are provided to patients with radiation-induced xerostomia undergoing treatment with drug under the Exceptional Access Program by Ontario Ministry of Health and Long-Term Care.
Xerostomia Therapeutics Market Trends, Drivers, Restraints, and Opportunities
- Increasing acceptance of radiotherapy and chemotherapy in cancer treatment with increasing use of prescribed medications are some of the key factors expected to fuel the market growth.
- Easy available and cost-effective medications are some of the key drivers of the market.
- Favorable government policies such as easy accessibility to reimbursement policies and other favorable policies of the patients are expected to accelerate the market expansion.
- Certain advantages such as safety & efficacy, availability of limited branded drugs, wide variety & availability, and low pricing of products are other key drivers of the market growth.
Scope of Xerostomia Therapeutics Market Report
The report on the global xerostomia therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Xerostomia Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Types (Over the counter and Prescription) and Products (Salivary Stimulants, Dentifrices, and Salivary Substitutes)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Church & Dwight Co., Inc.; GlaxoSmithKline Plc; Hikma Pharmaceuticals Plc; Pendopharm, Inc; Sun Pharmaceuticals Industries Ltd.; Pfizer, Inc.; Parnell Pharmaceuticals, Inc.; Lupin Pharmaceuticals, Inc.; Colgate-Palmolive Company; OraCoat; and Acacia Pharma Ltd.
|
Xerostomia Therapeutics Market Segment Insights
Type Segment Analysis
Based on types, the global xerostomia therapeutics market is divided into over the counter (OTC) and prescription. The OTC segment is expected to grow at a rapid pace in the coming years owing to safety & efficacy, wide variety & availability, and low pricing of products of OTC drugs.
However, the prescription segment is anticipated to accounts for a key share of the market during the forecast period due to the adoption by large number of medical practitioners.
Product Segment Analysis
On the basis of products, the market is divided into salivary stimulants, dentifrices, and salivary substitutes. The dentifrices segment is projected to expand at a considerable CAGR during the projected period due to its easy availability, effectiveness, affordability, and higher adoption among end users.
Meanwhile, the salivary stimulants segment is anticipated to grow at a substantial rate during the forecast period owing to wide range of products and substitutes along with easy availability.
Regional Outlook
In terms of regions, the global xerostomia therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of the North America is anticipated to constitute a key market share during the targeted years owing to increasing incidences of xerostomia and increasing dry mouth awareness initiatives in the region.
The market of Asia Pacific, however, is anticipated to expand at a robust growth rate during the forecast period due to growing healthcare expenditure and various growing initiatives by governments across the region.
Segments
The global xerostomia therapeutics market has been segmented on the basis of
Types
- Over the counter
- Prescription
Products
- Salivary stimulants
- Dentifrices
- Salivary substitutes
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Church & Dwight Co., Inc.
- GlaxoSmithKline Plc
- Hikma Pharmaceuticals Plc
- Pendopharm, Inc.
- Sun Pharmaceuticals Industries Ltd.
- Pfizer, Inc.
- Parnell Pharmaceuticals, Inc.
- Lupin Pharmaceuticals, Inc.
- Colgate-Palmolive Company
- OraCoat
- Acacia Pharma Ltd.
Competitive Landscape
Key players competing in the global xerostomia therapeutics market are Church & Dwight Co., Inc.; GlaxoSmithKline Plc; Hikma Pharmaceuticals Plc; Pendopharm, Inc; Sun Pharmaceuticals Industries Ltd.; Pfizer, Inc.; Parnell Pharmaceuticals, Inc.; Lupin Pharmaceuticals, Inc.; Colgate-Palmolive Company; OraCoat; and Acacia Pharma Ltd.
The main market players are continuously engaged in the activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations.
For instance, a major oral care company, Hikma Pharmaceuticals acquired Roxane Laboratories, a part of West-Ward Pharmaceuticals Corp in April 2017 to enhance the product portfolio.
Request For Customization
Enquiry Before Buying
Speak With Analyst
